Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Bancroft Robert E., holds the title of President and CEO at AEON Biopharma, Inc..
On 2026-11-19, the insider transacted 152,333 shares.The shares were transacted at a weighted average price of $0.13 per share, resulting in a total market-relevant value of $20K.
Bancroft Robert E. (President and CEO) bought $20K of $AEON
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.